FY2022 · ended Dec 31, 2022 · Revenue $0 · Filed Mar 29, 2024
Processa Pharmaceuticals, Inc. (PCSA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue (TTM)
$0
Net income (TTM)
$-21.73M
-23.5% vs year-ago TTM
Operating cash flow (TTM)
$-11.97M
-10.3% vs year-ago TTM
Free cash flow
$-11.25M
-39.5% vs prior year
EPS
$-10.36
+89.3% vs prior year
Dividend per share
None
Shares outstanding
2.74M
+3.0% vs prior year
Net cash
$1.12M
FY 2024
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PCSA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Vero Beach, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1533743
- Former names
- Heatwurx, Inc. (until Oct 20, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 |
| Operating income | -$14.0M | -$12.1M | -$11.5M | -$27.5M | -$12.1M |
| Net income | -$13.6M | -$11.9M | -$11.1M | -$27.4M | -$11.4M |
| Diluted EPS | -$10.36 | -$96.78 | -$8.48 | — | — |
| Operating cash flow | -$11.4M | -$11.2M | -$8.1M | -$9.6M | -$8.7M |
| Free cash flow | — | -$11.2M | -$8.1M | — | — |
| Total assets | $7.8M | $3.2M | $5.8M | $8.6M | $26.5M |
| Total liabilities | $2.2M | $1.5M | $797,484 | $1.1M | $978,405 |
| Stockholders' equity | $5.6M | $1.7M | $5.0M | $7.5M | $25.5M |
| Cash and investments | $5.5M | $1.2M | $4.7M | $6.5M | $16.5M |
| Total debt | — | $73,507 | $150,554 | $229,450 | $78,463 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Nov 4, 2026 | Nov 2, 2026 |
| 8-K |
Current report
Other events
|
Oct 29, 2026 | Oct 27, 2026 |
| 8-K/A |
Amended current report
Other events
|
Oct 5, 2026 | Jul 23, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Aug 4, 2026 | Jul 30, 2026 |
All 705 Processa Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.